English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Conference Paper

A novel epigenetic resistance mechanism to the FLT3 inhibitor PK412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML).

MPS-Authors
/persons/resource/persons185577

Pan,  K. T.
Research Group of Bioanalytical Mass Spectrometry, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons15947

Urlaub,  H.
Research Group of Bioanalytical Mass Spectrometry, MPI for Biophysical Chemistry, Max Planck Society;

External Ressource
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Göllner, S., Agrawal-Singh, S., Oellerich, T., Schenk, T., Rohde, C., Klein, H. U., et al. (2016). A novel epigenetic resistance mechanism to the FLT3 inhibitor PK412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML). Haematologica, 101(Suppl. 1), 166-166.


Cite as: http://hdl.handle.net/11858/00-001M-0000-002B-2E82-9
Abstract
There is no abstract available